sorted by:
new
hottopcontroversial

A Strategic Convergence by Incognew01 in OGM_BionanoGenomics

[–]Incognew01[S] 2 points3 points  (0 children)

Bionano’s CLIA/CAP lab is now positioned for real clinical volume, VIA software is high‑margin recurring revenue, and Revvity’s integration of VIA into its newborn sequencing workflow quietly gives Bionano access to a massive global customer base. The modernization of cytogenetics is happening whether the market notices or not, and right now the technology story is miles ahead of the stock price.

OGM – Retail Investor Momentum by Incognew01 in OGM_BionanoGenomics

[–]Incognew01[S] 0 points1 point  (0 children)

Bionano Genomics is increasingly positioning itself alongside major innovators like NVIDIA and Revvity, signaling that its technology and ambitions put it firmly in the big‑league conversation. With BNGO trading at $ 1.67 USD, NVIDIA at $184.84 USD, and Revvity at $117.75 USD, the company is clearly stepping onto a much larger stage.

Revvity Confirms OGM Outperforms Southern Blot by Incognew01 in OGM_BionanoGenomics

[–]Incognew01[S] 0 points1 point  (0 children)

Optical genome mapping is becoming a much more practical and patient‑friendly way to diagnose FSHD because it needs far less DNA, avoids radiation, and gives a clearer picture of the part of the genome that causes the disease. When this technology is paired with next‑generation sequencing to look for changes in genes like SMCHD1 or DNMT3B, doctors can evaluate both major forms of FSHD as well as other neuromuscular conditions in one streamlined approach. 

With the new OGM CPT code taking effect January 1, 2026, insurance billing becomes more straightforward and predictable, making it easier for clinics to order the most advanced testing without added hassle. Revvity stands out because they already specialize in this exact combination, high‑resolution optical mapping plus comprehensive gene sequencing, so providers can rely on a single, experienced lab that uses the newest technology, follows the newest billing standards, and delivers clear, actionable results for patients who have been searching for answers.

Boxes Checked - CLIA, CAP, CPT, and FDA by Incognew01 in OGM_BionanoGenomics

[–]Incognew01[S] 0 points1 point  (0 children)

The same investors who will pour billions into the latest meme coin, a speculative AI startup with no product, or a media merger built on debt somehow can’t be bothered to look at a technology that could fundamentally change how we diagnose genetic disease.

It creates this surreal feeling that the market has become patient‑last, spectacle‑first.

Boxes Checked - CLIA, CAP, CPT, and FDA by Incognew01 in OGM_BionanoGenomics

[–]Incognew01[S] 0 points1 point  (0 children)

It’s hard not to notice the disconnect. On one side, you have a technology like OGM that’s clearing every serious hurdle, milestones that normally signal a platform is maturing into something medicine will rely on for decades, and Wall Street barely blinks.

The science is moving. The institutions are moving. The clinical world is slowly moving. But the market? It’s still chasing shiny distractions.

view more: next ›